NCT06966674 No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
| NCT ID | NCT06966674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kafrelsheikh University |
| Condition | No-Reflow |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-05-12 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-05-12 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old. * Both sexes. * Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block. Exclusion Criteria: * Treatment with thrombolytic drugs in the previous 24 hours. * Known malignancy. * Thrombocytopenia. * End-stage liver disease. * Cardiogenic shock. * Renal failure with glomerular filtration\<30 ml/min. * Contraindication for the use of tirofiban.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06966674 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying No-Reflow. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06966674 currently recruiting?
Yes, NCT06966674 is actively recruiting participants. Contact the research team at drhammad879@gmail.com for enrollment information.
Where is the NCT06966674 trial being conducted?
This trial is being conducted at Kafr ash Shaykh, Egypt.
Who is sponsoring the NCT06966674 clinical trial?
NCT06966674 is sponsored by Kafrelsheikh University. The trial plans to enroll 60 participants.